IAPT Rec'd PCTIPTO 30 MAR 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER 2335.0140000/SRL/KPQ

ARPLICATIONING. (Irknown see 37 CFR 1.5)

Diagnostic and Therapeutic Use of a Sulfotransferase for Neurodegenerative Diseases APPLICANT(S) FOR ODEOUS Heinz VON DER KAMMER and Johannes POHLNER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: X				in a significant		
Diagnostic and Therapeutic Use of a Sulfotransferase for Neurodegenerative Diseases APPLICANT(S) FOR ODEGIUS Heinz VON DER KAMMER and Johannes POHLNER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: X						
Heinz VON DER KAMMER and Johannes POHLNER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1.	TITLE OF INVENTION Diagnostic and Therapeutic Use of a Sulfotransferase for Neurodegenerative Diseases					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1.	APPLICANT(S) FOR DO/EO/US					
2.	Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
3.	1. X	This is a FIRST submission of items co	oncerning a submission under 35 U.S.C. 371	l.		
(5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or Information Included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. A substitute specification. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821-1.825.	2.	This is a SECOND or SUBSEQUENT s	submission of items concerning a submission	n under 35 U.S.C. 371.		
5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a.	3. 🗓					
a.	4. X	The US has been elected (Article 31).				
b. X has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13fer.2 and 37 CFR 1.821-1.825.	5. X	A copy of the International Application as filed (35 U.S.C. 371(c)(2))				
c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X		a. is attached hereto (required only if not communicated by the International Bureau).				
An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of altorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).		b. X has been communicated by the International Bureau.				
a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13/er/2 and 37 CFR 1.821-1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).		c. is not required, as the application was filed in the United States Receiving Office (RO/US).				
b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or Information Included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821-1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).	6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).				
Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).		a. is attached hereto.				
a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	_	b. has been previously submitted under 35 U.S.C. 154(d)(4).				
b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))				
c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).		a. are attached hereto (required only if not communicated by the International Bureau).				
d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).		b. have been communicated by the International Bureau.				
An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4).		c. have not been made; however, the time limit for making such amendments has NOT expired.				
9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13fer.2 and 37 CFR 1.821- 1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).		d. Light have not been made and	will not be made.			
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or Information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).				
Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).	9. X	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).				
An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	10.		e annexes of the International Preliminary E	examination Report under PCT		
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	items	s 11 to 20 below concern document(s	s) or information included:			
13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).	11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.			
An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	12.	An assignment document for recording	ng. A separate cover sheet in compliance wi	ith 37 CFR 3.28 and 3.31 is included.		
A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	13. 🗓	A preliminary amendment.				
A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4).		An Application Data Sheet under 37 CFR 1.76.				
17. X A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825. 18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).	15.	A substitute specification.				
18. X A second copy of the published International Application under 35 U.S.C. 154(d)(4).	16.	A power of attorney and/or change of address letter.				
	17. 🗓	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.				
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).		A second copy of the published Inter-	national Application under 35 U.S.C. 154(d)	(4).		
	19.	A second copy of the English langua	ge translation of the international application	n under 35 U.S.C. 154(d)(4).		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Page 1 of 3

IAPZORCEUPOTITTO 30 MAR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

20. Other items or information:							
20. Other items or information: 1) Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3); 2) Paper Copy of Sequence Listing; 3) Copy of International Search Report; and 4) Two (2) return postcards.							
The following fees have been submitted CALCULATIONS P	PTO USE ONLY						
21. X Basic national fee (37 CFR 1.492(a))							
22. X Examination fee (37 CFR 1.492(c))							
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							
23. X Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority							
All other situations							
TOTAL OF 21, 22 and 23 = 900,00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding							
sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole number)							
82 - 100 = /50 = x \$250 \$							
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).							
CLAIMS NUMBER FILED NUMBER EXTRA RATE \$							
Total claims 30 - 20 = 10 x \$ 50 \$ 500.00							
Independent claims 8 - 3 = 5 x \$200 \$ 1,000.00							
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360 \$							
TOTAL OF ABOVE CALCULATIONS = \$ 1,500.00							
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.							
SUBTOTAL = \$ 2,400.00							
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).							
TOTAL NATIONAL FEE = $\$$ 2,400.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +							
TOTAL FEES ENCLOSED = \$ 2,400.00							
Amount to be refunded:	\$						
Amount to be charged	\$						

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$	_ to cover the above tees is enclosed.			
b. Please charge my Deposit Account NoA duplicate copy of this sheet is enclosed.	in the amount of \$ to cover the above fees.			
c. X The Commissioner is hereby authorized to charge any Account No. <u>19-0036</u> . A duplicate copy of this si	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0036. A duplicate copy of this sheet is enclosed.			
d. X Fees are to be charged to a credit card. WARNING: I be included on this form. Provide credit card inform	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.				
SEND ALL CORRESPONDENCE TO:	SIGNATURE P. CO.			
CUSTOMER NUMBER 26111	Katrina Y. Pei Quach			
	51,063 REGISTRATION NUMBER			

497304_1.HFD